Key result
Rivaroxaban was associated with a significantly lower risk of recurrent VTE compared to LMWH (HR 0.72) and warfarin (HR 0.74) in cancer patients, with similar rates of major bleeding.
Why the study?
Does rivaroxaban reduce VTE recurrence compared to LMWH or warfarin in cancer patients with VTE?
Population
2,428 newly diagnosed cancer patients with a first venous thromboembolism between 1/1/2013 and 05/31/2015…
Comparison
Rivaroxaban initiated within 7 days of VTE… vs Low-molecular-weight heparin or warfarin
Design
Cohort
Follow-up
up to 12 months
Authors
Loading...
May support rivaroxaban preference in cancer-associated VTE; leaves open randomized confirmation before practice change.
Cohort (n=2,428)
Does rivaroxaban reduce VTE recurrence compared to LMWH or warfarin in cancer patients with VTE?
Hazard Ratio: 0.72 (95% CI 0.52–0.95)
Absolute Event Rate: 16.5% vs 22.2%
p-value: p=0.024
In a real-world cohort of cancer patients with VTE, rivaroxaban significantly reduced the risk of recurrent VTE compared to LMWH or warfarin without increasing major bleeding.
Streiff et al. (2018) conducted a cohort in Venous thromboembolism in patients with cancer (n=2,428). Rivaroxaban vs. Low-molecular-weight heparin (LMWH) was evaluated on VTE recurrence (HR 0.72, 95% CI 0.52-0.95, p=0.024). Rivaroxaban was associated with a significantly lower risk of recurrent VTE compared to LMWH (HR 0.72) and warfarin (HR 0.74) in cancer patients, with similar rates of major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: